GSK PLC ADR (GSK) News
Filter GSK News Items
GSK News Results
|Loading, please wait...|
GSK News Highlights
- For GSK, its 30 day story count is now at 22.
- Over the past 24 days, the trend for GSK's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- SNY, DRUG and TOP are the most mentioned tickers in articles about GSK.
Latest GSK News From Around the Web
Below are the latest news stories about GSK PLC that investors may wish to consider to help them evaluate GSK as an investment opportunity.
A story of cancer scares, secretive short sellers, psychological tape bombs and post-investment stress disorder
In this article, we will be taking a look at the 25 countries with highest life expectancy. To skip our detailed analysis, you can go directly to see 10 Countries with Highest Life Expectancy. In just the past two decades, 2000 — 2019, the average global life expectancy increased from 66.8 years to 73.4 years […]
In this article, we discuss 10 best biotech stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy According To Hedge Funds. In 2023, digitalization will increase in the biotech industry as the possibility of online and remote assessment, diagnosis, […]
In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […]
The following are the top stories on the business pages of British newspapers. A potential blockbuster blood cancer treatment Blenrep being developed by GSK Plc is to be removed from the American market after a request from regulators. Cristiano Ronaldo has left Manchester United Plc without receiving any compensation after the two parties agreed to rip up his contract.
GSK plc (NYSE: GSK) has initiated the withdrawal process of the U.S. marketing authorization for Blenrep (belantamab mafodotin-blmf) following the FDA request. This request was based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial, which did not meet the requirements of the FDA Accelerated Approval regulations. Blenrep is a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies. Also see
The pharmaceutical giant said the request comes after its Dreamm-3 Phase 3 study didn't meet its primary endpoint of progression-free survival.
GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, in another setback for the British drugmaker's oncology business. The company had said this month that Blenrep had failed the main goal of a key study designed to show it was better than an existing treatment on the market, stoking fears that regulatory approval could be rescinded by the U.S. Food and Drug Administration (FDA). On Tuesday GSK said it has begun the process to withdraw Blenrep's marketing authorisation in the country but would continue trial programmes for the drug, adding that some patients would have the option to enrol for continued access to the treatment.
In this article, we will take a look at billionaire Steve Cohen’s top dividend stocks. If you want to see more of billionaire Steve Cohen’s top dividend stocks, go directly to Billionaire Steve Cohen’s Top 5 Dividend Stocks. Billionaire Steve Cohen is the founder of Point72 Asset Management which as of the end of September […]
Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.